论文部分内容阅读
目的:比较经尿道铥激光前列腺剜除术(Thu VEP)和经尿道等离子前列腺剜除术(TUKEP)在治疗大体积前列腺增生(>80 m L)的效果及安全性。方法:136例前列腺增生患者被分成两组,分别进行Thu VEP及TUKEP治疗。观察并比较两组的血红蛋白、血清Na+、手术时间、术后留置尿管时间、术后住院时间、国际前列腺症状评分(IPSS)、生活质量评分(QOL)、最大尿流率(Qmax)、残余尿(PVR)及并发症等。结果:Thu VEP组血红蛋白下降值、血清Na+下降值、术后住院时间、术后保留尿管时间等较TUKEP组减少,有统计学意义,但是手术时间两组无统计学差异。两组患者术后IPSS评分、QOL评分、Qmax及PVR比较无统计学差异。两组术后并发症发生率无明显差异。结论:与TUKEP相比,在治疗大体积前列腺增生时Thu VEP更为安全,止血效果更好,失血量更少。
OBJECTIVE: To compare the efficacy and safety of transurethral laser thrombectomy (Thu VEP) and transurethral plasmapapillary excision (TUKEP) in the treatment of large-volume benign prostatic hyperplasia (> 80 m L). Methods: Thirty-six patients with benign prostatic hyperplasia were divided into two groups and were treated with Thu VEP and TUKEP respectively. The levels of hemoglobin, serum Na +, operation time, postoperative indwelling catheter time, postoperative hospital stay, IPSS, QOL, Qmax, Urine (PVR) and complications. Results: Thu VEP group decreased hemoglobin, serum Na + decreased, postoperative hospital stay, postoperative retention catheter time than the TUKEP group decreased, statistically significant, but the operation time was no significant difference between the two groups. There was no significant difference in IPSS score, QOL score, Qmax and PVR between the two groups. No significant difference in the incidence of postoperative complications between the two groups. CONCLUSIONS: Thu VEP is safer, has better hemostasis and has less blood loss in treating massive BPH than TUKEP.